康哲藥業(00867)獲得1類新藥MG-K10人源化單抗注射液新增慢性阻塞性肺疾病適應症藥物臨牀試驗批准通知書

智通財經

09/30

智通財經APP訊，康哲藥業(00867)公佈，集團擁有共同開發權(除特應性皮炎(AD)外)及獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液(MG-K10)於2025年9月29日獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書， NMPA同意開展MG-K10用於慢性阻塞性肺疾病(COPD)的臨牀試驗。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571347026"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571347026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571347026?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-30 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571347026","market":"hk","top_or_hot":-1,"title":"康哲藥業(00867)獲得1類新藥MG-K10人源化單抗注射液新增慢性阻塞性肺疾病適應症藥物臨牀試驗批准通知書","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/00867\">康哲藥業</a>(00867)公佈，集團擁有共同開發權(除特應性皮炎(AD)外)及獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液(MG-K10)於2025年9月29日獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書， NMPA同意開展MG-K10用於慢性阻塞性肺疾病(COPD)的臨牀試驗。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲藥業(00867)獲得1類新藥MG-K10人源化單抗注射液新增慢性阻塞性肺疾病適應症藥物臨牀試驗批准通知書</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲藥業(00867)獲得1類新藥MG-K10人源化單抗注射液新增慢性阻塞性肺疾病適應症藥物臨牀試驗批准通知書\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-09-30 20:37</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/00867\">康哲藥業</a>(00867)公佈，集團擁有共同開發權(除特應性皮炎(AD)外)及獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液(MG-K10)於2025年9月29日獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書， NMPA同意開展MG-K10用於慢性阻塞性肺疾病(COPD)的臨牀試驗。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1351489.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999015986.USD","symbol_name":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1351489.html","article_id":"2571347026","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571347026","pubTimestamp":1759235825,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，康哲藥業(00867)公佈，集團擁有共同開發權(除特應性皮炎(AD)外)及獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液(MG-K10)於2025年9月29日獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書， NMPA同意開展MG-K10用於慢性阻塞性肺疾病(COPD)的臨牀試驗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK4123":"调查和咨询服务","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK1191":"制药","BK1593":"医美概念股","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","00867":"康哲药业","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","MG":"Mistras Group","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC"},"translate_title":"Kangzhe Pharmaceutical (00867) obtained the approval notice for clinical trials of Class 1 new drug MG-K10 humanized monoclonal antibody injection for new chronic obstructive pulmonary disease indications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1.5,"MG":1.5},"content_text":"智通財經APP訊，康哲藥業(00867)公佈，集團擁有共同開發權(除特應性皮炎(AD)外)及獨家商業化權利的1類新藥抗IL-4Rα MG-K10人源化單抗注射液(MG-K10)於2025年9月29日獲中國國家藥品監督管理局(NMPA)簽發的藥物臨牀試驗批准通知書， NMPA同意開展MG-K10用於慢性阻塞性肺疾病(COPD)的臨牀試驗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}